Vimarsana
Biggest News Aggregation in the World

Channel Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Channel Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Channel Bio Today - Breaking & Trending Today

ALJAZ NEWSHOUR July 14, 2024 - Vimarsana News

ALJAZ NEWSHOUR July 14, 2024

Had a mostly fine across much of the middle east we have there been seeing some areas of trad working their way towards the caspian sea in the last few hours and again we may will just have some more showers working their way through the east and then the black sea as we had on 3 monday they could linger on into tuesday elsewhere it is false and it is dry but notice assholes in baghdad 43 degrees celsius on choose a 46. 00 however in a queue a city further to the south the temperatures are highs you might expect so we will flow pushing into areas of amman also pushing on the cloud as well but ...

CNNW CNN Newsroom With Fredricka Whitfield April 9, 2017 - Vimarsana News

CNNW CNN Newsroom With Fredricka Whitfield April 9, 2017

Local media says the head of egypts church was inside when that attack happened. Meanwhile, the u. S. Mounting a show of force sending war ships toward the Korean Peninsula in response to nourgt korrth korea missile test just days agriculture as Rex Tillerson travels to moscow to meet with his russian counterpart. The chemical attack in syria and what happens next as the Trumps Administration policy on dealing with the president seems to depend on who you ask. Ten days ago you said getting assad out of sore was not a priority. But im trying to figure out is regime change in syria now the offic...

Biohaven pays $100M for epilepsy drug prospect; strikes deal for BMS muscle med - Vimarsana News

Biohaven pays $100M for epilepsy drug prospect; strikes deal for BMS muscle med

Neuroscience drug developer Biohaven Pharmaceuticals is expanding its pipeline to include epilepsy and spinal muscular atrophy. The drug developer is acquiring Channel Bioscience and licensing global rights to a Phase 3-ready drug from Bristol Myers Squibb.